Celcuity cash support for potential commercial launch of gedatolisib with FDA alignment to expand Phase 3

Celcuity posts Q1 2026 net loss of $52.8M ($0.97/share), ends with $387.1M cash and expects resources to fund operations through 2027

Net loss widened year over year due to higher research and development and SG&A spending. Company says cash resources should support preparation for potential commercial launch of gedatolisib. Celcuity obtained FDA alignment to expand Phase 3 VIKTORIA-2 gedatolisib trial with new first-line HR+/HER2- cohort.

https://finviz.com/quote?t=CELC&p=d